Enhertu's New Role: Early Treatment Boost for Metastatic Breast Cancer
Insights from ASCO Annual Meeting on Enhertu and Advanced Treatment Strategies
Topline:
Enhertu (trastuzumab deruxtecan) shows promise in improving progression-free survival for women with HER2-low hormone receptor-positive metastatic breast cancer, suggesting earlier use in treatment protocols.
Study Details:
Recent findings presented at the American Society of Clinical Oncology (ASCO) annual meeting shed light on significant advanc…
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.